Compounds > debrisoquin

debrisoquin and propafenone

debrisoquin has been researched along with propafenone in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (10.00)	18.7374
1990's	7 (70.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	1 (10.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Belloni, M; Bernasconi, R; Cappiello, E; Castel, JM; Giani, P; Landolina, M; Latini, R; Leopaldi, D	1
Ambrosioni, E; Boriani, G; Boschi, S; Capucci, A; Frabetti, L; Magnani, B; Strocchi, E	1
Ambrosioni, E; Balducelli, M; Boriani, G; Capucci, A; Frabetti, L; Magnani, B; Marchesini, B; Strocchi, E; Tomasi, L	1
McAllister, CB; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Wilkinson, GR; Woosley, RL	1
Griese, EU; Kuhlmann, U; Machleidt, C; Magadum, S; Mettang, T; Mörike, K	1
Johnston, A; Lledó, P; Pearson, RM; Turner, P; Walker, S	1
Ebner, T; Eichelbaum, M	1
Alken, RG; Koytchev, R; Mayer, O	1
Dorne, JL; Renwick, AG; Slob, W; Walton, K	1

Trials

1 trial(s) available for debrisoquin and propafenone

Article	Year
Effect of diprafenone on the pharmacokinetics of digoxin. European journal of clinical pharmacology, 1996, Volume: 50, Issue:1-2 Topics: Adrenergic Agents; Adult; Anti-Arrhythmia Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Digoxin; Drug Interactions; Humans; Male; Mixed Function Oxygenases; Phenotype; Propafenone	1996

Other Studies

9 other study(ies) available for debrisoquin and propafenone

Article	Year
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Identification of propafenone metaboliser phenotype from plasma and urine excretion data. European journal of clinical pharmacology, 1992, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Debrisoquin; Female; Humans; Hydroxylation; Male; Middle Aged; Phenotype; Propafenone	1992
[Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone]. Cardiologia (Rome, Italy), 1990, Volume: 35, Issue:2 Topics: Adult; Aged; Debrisoquin; Humans; Italy; Middle Aged; Oxidation-Reduction; Phenotype; Propafenone	1990
Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. Cardiovascular drugs and therapy, 1990, Volume: 4, Issue:1 Topics: Administration, Oral; Adult; Aged; Debrisoquin; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Phenotype; Propafenone; Time Factors	1990
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation, 1987, Volume: 75, Issue:4 Topics: Adult; Aged; Arrhythmias, Cardiac; Cytochrome P-450 CYP2D6; Debrisoquin; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; In Vitro Techniques; Kinetics; Liver; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Propafenone; Time Factors	1987
Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Journal of internal medicine, 1995, Volume: 238, Issue:5 Topics: Aged; Anti-Arrhythmia Agents; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Genotype; Humans; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Propafenone; Sparteine; Time Factors	1995
Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios. Human & experimental toxicology, 1993, Volume: 12, Issue:2 Topics: Adult; Chromatography, Gas; Debrisoquin; Female; Humans; Male; Oxidation-Reduction; Phenotype; Propafenone	1993
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism. British journal of clinical pharmacology, 1993, Volume: 35, Issue:4 Topics: Aprindine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Propafenone; Quinidine; Sparteine	1993
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11 Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride	2002